Blood Test Monitoring of Treatment in Advanced Lung Cancer
Tests blood-based tumor DNA monitoring in adults with advanced non-small cell lung cancer on immunotherapy.
Plain-language title generated from the registry record
Registry title: Circulating Tumor DNA Guided Treatment Monitoring in Advanced Lung Cancer
Key facts
- Where
- Aalborg, Hillerød, Næstved, Roskilde, and Vejle, DenmarkSee the 5 sites
Where in Denmark
- Department of OncologyAalborg, DenmarkNot yet recruiting
- Department of Clinical OncologyHillerød, DenmarkTaking people
- Department of Clinical Oncology and Palliative CareNæstved, DenmarkTaking people
- Department of Clinical Oncology and Palliative CareRoskilde, DenmarkTaking people
- Department of OncologyVejle, DenmarkNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Zealand University Hospital
- Trial code
- NCT05889247
- Record updated
- 9 January 2026
- Original description
The study is a prospective randomized interventional study including patients with advanced non-small cell lung cancer, receiving immunotherapy, with the aim of optimizing treatment monitoring. The study aims to investigate the clinical utility of liquid biopsy monitoring in order to reduce the numbers of inefficient treatments and needless toxicity - and to explore the cost-effectiveness and cost-utility of introducing liquid biopsy monitoring in daily clinical practice.Read full original descriptionShow less
Circulating Tumor DNA Guided Treatment Monitoring in Advanced Lung Cancer - a Randomized Interventional Study
The study is a prospective randomized interventional study including patients with advanced non-small cell lung cancer, receiving immunotherapy, with the aim of optimizing treatment monitoring. The study aims to investigate the clinical utility of liquid biopsy monitoring in order to reduce the numbers of inefficient treatments and needless toxicity - and to explore the cost-effectiveness and cost-utility of introducing liquid biopsy monitoring in daily clinical practice.
Inclusion: Newly diagnosed, histologically verified, Non-Small Cell Lung Cancer (NSCLC); Advanced or locally advanced disease without curative intended treatment options; Age > 18 years; Eastern Cooperative Oncology Group (ECOG) score of Performance Status (PS) 0-1; Measurable disease according to the iRECIST criteria version 1.1; Eligible to first line immunotherapy (monotherapy); Signed informed consent.
Exclusion: Other active cancers; Targetable alterations in EGFR, ALK or ROS-1.